Drugnews
Drugnews
2026-11-19
Chinese
Complete free industry report

Asia protein degraders 2026 — who has human data

Executive summary

Japan’s Astellas and China-origin BeOne have the late-stage programs to watch. Astellas has published early human tumor responses for setidegrasib and is testing it in randomized lung and pancreatic cancer studies. BeOne has presented responses for tacabrutideg and reported that its pivotal Phase 2 cohort met its response endpoint. China’s Kintor already has a different kind of evidence in hair loss: a completed randomized trial with a vehicle control. [P01] [P02] [P03] [P22] [P23] [P24] [P25]

A trial phase and an outcome answer different questions

The comparison covers 18 selected assets across China, Japan and South Korea. For each, the table asks the same questions. Who originated the asset? Which target and modality does it use? How far has its protocol progressed? What outcome has been disclosed, in which population and under which comparator? Is an asset-specific license public? The phase and evidence columns remain independent. A completed study establishes that participants were exposed. An interpretable result needs enough detail to identify the measured outcome and the population. [P00]

PROTAC recruitment, tagging and degradation
PROTAC recruitment, tagging and degradation

A conventional heterobifunctional degrader can recruit an E3 ubiquitin ligase to a target protein. The resulting proximity can lead to target tagging with ubiquitin and removal by the proteasome. A molecular glue can stabilize an interaction between a ligase and a target in a different way. A degrader–antibody conjugate adds a delivery step. The clinical question stays specific to the intended target, tissues and patient population. FDA approvals illustrate the scope. In May, the FDA approved vepdegestrant for a defined ESR1-mutated advanced breast cancer population after prior endocrine therapy. In August, it granted accelerated approval to iberdomide in a specified multiple-myeloma combination. Each decision applies to its labeled use and evidence package. [P20] [P21] [P30]

Common evidence scale from protocol to randomized outcome
Common evidence scale from protocol to randomized outcome

Japan and China have late-stage tests with different endpoints

Tacabrutideg is a BTK degrader. In BeOne’s open-label CaDAnCe-101 Phase 1 CLL/SLL cohort presented at EHA, 57 of 67 patients responded under criteria that included partial response with lymphocytosis, an 85.1% overall response rate. In November, BeOne said the pivotal Phase 2 component met its primary response endpoint in relapsed or refractory CLL. The open-label response evidence supports further development. The Phase 3 comparison against pirtobrutinib asks whether the degrader improves progression-free survival against a treatment patients can already receive. Two of the reviewed Phase 3 studies are recruiting, and one is active without further recruitment. The reviewed registries have posted no Phase 3 results. [P01] [P22] [P23]

Astellas’s setidegrasib targets KRAS G12D. The published Phase 1 study reported an objective response rate of 37.5% in 32 patients receiving second- or third-line treatment for non-small-cell lung cancer in the cited cohort, and 24% in 21 second- or third-line patients in the cited pancreatic cancer cohort. These cohorts describe single-arm activity in two different diseases. In pancreatic cancer, the Phase 3 trial adds setidegrasib or placebo to chemotherapy and uses overall survival as the primary outcome. In previously treated lung cancer, the randomized trial compares setidegrasib with docetaxel and tracks progression-free and overall survival as primary outcomes. [P02] [P24]

What the registrational trials compare
What the registrational trials compare

For the late-stage programs, the next change in evidence comes when a randomized trial reports. The primary endpoint, treatment line, comparator and enrolled population will determine the claim each readout can support. The response rates above belong to their own cohorts. A pooled ranking would reward differences in tumor type and trial design.

Oral prostate cancer programs and topical hair-loss trials

China’s androgen receptor assets already show why the route and disease belong next to each other in the comparison. Hinova’s HP518, Qilu’s QLH12016 and Hengrui’s HRS-5041 have reported early human observations in metastatic prostate cancer. Those datasets include open-label safety, pharmacokinetics and preliminary activity or prostate-specific antigen responses. The later-stage label attached to a combination protocol and the result from an earlier monotherapy cohort can both be correct descriptions of the same asset. Hinova’s current registry and issuer disclosure also carry different information about the proposed suspension of a China monotherapy study. [P05] [P06] [P07] [P31] [P32] [P33]

Kintor’s GT20029 addresses androgenetic alopecia with a topical treatment. Its China Phase 2 study enrolled 180 men and assessed change in non-vellus target-area hair count after 12 weeks against vehicle. The trial has a peer-reviewed efficacy report. Kintor also reported that a separate China acne Phase 2 trial reached its primary endpoint. Prostate-specific antigen change, hair count and acne endpoints are three disease-specific measurements. Each requires its own comparator and a tolerability profile appropriate for the intended use. [P03] [P25] [P34]

Oral oncology and topical dermatology answer different clinical questions
Oral oncology and topical dermatology answer different clinical questions
GT20029 Phase 2 hair-count endpoint
GT20029 Phase 2 hair-count endpoint

Korea shows why the deal must name the asset

The Korean clinical rows are early. Ubix’s UBX-303061 is recruiting in a Phase 1 study in relapsed or refractory B-cell malignancies. Pin Therapeutics announced first-patient dosing for its CK1α molecular glue PIN-5018 in South Korea. Orum dosed its first patient in the Phase 1 study of ORM-1153, a CD123-targeted GSPT1 degrader–antibody conjugate. These events establish that the programs have entered clinical development. Comparable efficacy readouts for those assets are still undisclosed in the reviewed evidence. [P13] [P18] [P19]

In 2023, BMS acquired rights to Orum’s earlier program, ORM-6151, with US$100 million upfront. Orum disclosed discontinuation of that program’s Phase 1 study in September 2026. ORM-1153 is a distinct drug candidate. Janssen’s 2026 research and licensing collaboration with Prazer is a platform agreement with deal-specific assets and financial terms undisclosed. Cullgen’s earlier Astellas platform collaboration involved discovery and options and carried a licensor-reported US$35 million upfront. It supplies no evidence of a license over Astellas’s setidegrasib or the named Cullgen clinical assets in this roster. [P16] [P17] [P19] [P27] [P28] [P29]

A phase milestone and a licensing event follow different clocks
A phase milestone and a licensing event follow different clocks

One comparison standard for all three markets

E0 indicates a registered or announced study without direct public confirmation of dose or interpretable outcomes in the reviewed source set. E1 marks documented dosing or completed exposure, which may include early safety, tolerability or drug exposure. E2 marks a public uncontrolled efficacy signal or a sponsor efficacy topline for which the controlled results are unavailable. E3 marks a public controlled efficacy result, limited to its actual comparator and endpoint. The score describes the highest outcome evidence reviewed for the asset. A higher study phase can sit beside a lower outcome tier, and a terminated protocol keeps its historic phase and current status.

Origin Originator / asset Target / modality Highest tracked phase and status Human evidence Asset licensing Evidence
China BeOne Medicines / BeiGene / Tacabrutideg (BGB-16673) BTK / CDAC / chimeric degrader Phase 3 · Two reviewed Phase 3 trials recruiting; one active, no longer recruiting E2 · Phase 1 CLL/SLL responses plus sponsor-reported pivotal Phase 2 topline in relapsed/refractory CLL; Phase 3 comparator outcomes undisclosed Not disclosed [P01] [P22] [P23]
Japan Astellas Pharma / Setidegrasib (ASP3082) KRAS G12D / PROTAC / protein degrader Phase 3 · Pancreatic and lung Phase 3 trials recruiting E2 · Peer-reviewed Phase 1 lung and pancreatic cancer response results; Phase 3 outcomes undisclosed Not disclosed [P02] [P24]
China Kintor Pharmaceutical Limited (Suzhou Kintor) / GT20029 Androgen receptor (AR) / PROTAC Phase 2 · China alopecia Phase 2 completed; acne Phase 2 topline disclosed E3 · Peer-reviewed randomized vehicle-controlled alopecia efficacy; sponsor-reported acne topline is a separate indication Not disclosed [P03] [P25] [P34]
China Hinova Pharmaceuticals Inc. / HP518 Androgen receptor (AR) / PROTAC Phase 1/2 · Registry lists China study recruiting; issuer reports proposed monotherapy suspension E2 · Peer-reviewed open-label Phase 1 in metastatic castration-resistant prostate cancer Not disclosed [P05] [P32]
China Qilu Pharmaceutical / QLH12016 AR / PROTAC Phase 1/2 · Combination study recruiting; separate trial not yet recruiting in registry E2 · ESMO Phase 1 abstract reports early PSA response in previously treated prostate cancer Not disclosed [P06] [P33]
China Hengrui / HRS-5041 AR / Degrader Phase 1 · Monotherapy and combination dose-finding records recruiting E2 · ASCO Phase 1 abstract reports early PSA response across dose cohorts in prostate cancer Not disclosed [P07] [P31]
China Jiangsu Hengrui Pharmaceuticals Co., Ltd. / HRS-1358 Estrogen receptor (ER) / PROTAC Phase 1/2 · Breast cancer combination protocol recruiting E0 · Interpretable human outcomes not disclosed in reviewed records Not disclosed [P08]
China BeOne Medicines / BeiGene / BGB-45035 IRAK4 / CDAC / chimeric degrader Phase 2, terminated · Rheumatoid arthritis trial terminated; prior Phase 1 completed E1 · Phase 1 exposure documented, arm-level efficacy undisclosed in reviewed records; termination cites unfavorable benefit-risk Not disclosed [P09]
China InnoCare Pharma / Beijing InnoCare Pharma Tech Co., Ltd. / ICP-490 IKZF1 (Ikaros); IKZF3 (Aiolos) / CRBN molecular glue Phase 1/2 · Multiple myeloma status unknown; lymphoma protocol not yet recruiting in registry E0 · Interpretable clinical outcomes not disclosed in reviewed records Not disclosed [P10]
China InnoCare Pharma / Beijing InnoCare Pharma Tech Co., Ltd. / ICP-538 VAV1 / CRBN molecular glue Phase 1 · Healthy-volunteer study recruiting in registry E0 · Human tolerability or pharmacodynamics outcomes not disclosed in reviewed records Not disclosed [P11]
China Haisco Pharmaceutical Group Co., Ltd. / HSK29116 Bruton tyrosine kinase (BTK) / PROTAC Phase 1 · Registry status unknown E0 · Interpretable human outcomes not disclosed in reviewed records Not disclosed [P12]
South Korea Ubix Therapeutics / UBX-303061 BTK / PROTAC / chimeric degrader Phase 1 · B-cell lymphoma study recruiting E0 · Public registry specifies dose and safety objectives; outcome readout undisclosed Not disclosed [P13]
China Haisco Pharmaceutical Group Co., Ltd. / HSK40118 Mutant epidermal growth factor receptor (EGFR) / PROTAC Phase 1 · Registry last listed recruitment in September 2023; current status uncertain E0 · Interpretable human outcomes not disclosed in reviewed records Not disclosed [P14]
China BeOne Medicines / BG-75098 CDK2 / CDAC Phase 1 · Solid tumor trial recruiting E0 · Interpretable human outcomes not disclosed in reviewed records Not disclosed [P15]
China Cullgen (Gyre Therapeutics / GNI Group) / CG001419 TRK / PROTAC / protein degrader Phase 1; Phase 1/2 protocol listed · Healthy-volunteer Phase 1 completed; China dose escalation within a Phase 1/2 protocol recruiting E1 · Human exposure documented; interpretable patient efficacy undisclosed Separate Cullgen platform arrangements are not attributed to this asset [P16] [P29]
China Cullgen (Gyre Therapeutics / GNI Group) / CG009301 GSPT1 / Protein degrader Phase 1 · China hematologic cancer dose escalation recruiting E0 · Interpretable human outcomes not disclosed in reviewed records Separate Cullgen platform arrangements are not attributed to this asset [P17] [P29]
South Korea Pin Therapeutics / PIN-5018 CK1α / Molecular glue degrader Phase 1 · Company announced first patient dosed in South Korea E1 · First dose documented by the sponsor; clinical outcomes undisclosed Not disclosed [P18]
South Korea Orum Therapeutics / ORM-1153 CD123 / GSPT1 / Degrader-antibody conjugate (DAC) Phase 1 · First patient dosed; registered study recruiting E1 · First dose documented; response outcomes undisclosed Signed asset license not disclosed; earlier ORM-6151 transaction tracked separately [P19] [P27]

Download the pipeline CSV. The table covers a selected roster. Origin follows the company that originated or leads the program, regardless of trial geography or later corporate ownership. For undisclosed terms and outcomes, the table records what could be verified at the cutoff. Registry status is timestamped and can lag a company filing. Asset rights and a separate platform collaboration have separate rows or explanatory notes.

The most consequential next evidence is an efficacy result against the intended comparator. For BTK that is a randomized study against an approved inhibitor. [P01]

Submit corrections with the registry ID or name of the agreement, the original document and the disclosure date. General research only. This report does not provide medical or investment advice.

Frequently asked questions

Which Chinese BTK degrader has human results and a Phase 3 head-to-head trial?

Tacabrutideg is a BTK degrader. In BeOne’s open-label CaDAnCe-101 Phase 1 CLL/SLL cohort presented at EHA, 57 of 67 patients responded under criteria that included partial response with lymphocytosis, an 85.1% overall response rate. In November, BeOne said the pivotal Phase 2 component met its primary response endpoint in relapsed or refractory CLL. The open-label response evidence supports further development. The Phase 3 comparison against pirtobrutinib asks whether the degrader improves progression-free survival against a treatment patients can already receive. Two of the reviewed Phase 3 studies are recruiting, and one is active without further recruitment. The reviewed registries have posted no Phase 3 results. [P01] [P22] [P23]

What human evidence does Astellas have for setidegrasib?

Astellas’s setidegrasib targets KRAS G12D. The published Phase 1 study reported an objective response rate of 37.5% in 32 patients receiving second- or third-line treatment for non-small-cell lung cancer in the cited cohort, and 24% in 21 second- or third-line patients in the cited pancreatic cancer cohort. These cohorts describe single-arm activity in two different diseases. [P24]

What Phase 3 comparators does Astellas have for setidegrasib?

In pancreatic cancer, the Phase 3 trial adds setidegrasib or placebo to chemotherapy and uses overall survival as the primary outcome. In previously treated lung cancer, the randomized trial compares setidegrasib with docetaxel and tracks progression-free and overall survival as primary outcomes. [P02]

Which Asian topical AR degrader has controlled hair-count data?

Kintor’s GT20029 addresses androgenetic alopecia with a topical treatment. Its China Phase 2 study enrolled 180 men and assessed change in non-vellus target-area hair count after 12 weeks against vehicle. The trial has a peer-reviewed efficacy report. Kintor also reported that a separate China acne Phase 2 trial reached its primary endpoint. Prostate-specific antigen change, hair count and acne endpoints are three disease-specific measurements. Each requires its own comparator and a tolerability profile appropriate for the intended use. [P03] [P25] [P34]

Which Korean degrader assets have started human trials, and how much is public?

The Korean clinical rows are early. Ubix’s UBX-303061 is recruiting in a Phase 1 study in relapsed or refractory B-cell malignancies. Pin Therapeutics announced first-patient dosing for its CK1α molecular glue PIN-5018 in South Korea. Orum dosed its first patient in the Phase 1 study of ORM-1153, a CD123-targeted GSPT1 degrader–antibody conjugate. These events establish that the programs have entered clinical development. Comparable efficacy readouts for those assets are still undisclosed in the reviewed evidence. [P13] [P18] [P19]

References

  1. P00
  2. P01
  3. P02
  4. P03
  5. P05
  6. P06
  7. P07
  8. P08
  9. P09
  10. P10
  11. P11
  12. P12
  13. P13
  14. P14
  15. P15
  16. P16
  17. P17
  18. P18
  19. P19
  20. P20
  21. P21
  22. P22
  23. P23
  24. P24
  25. P25
  26. P27
  27. P28
  28. P29
  29. P30
  30. P31
  31. P32
  32. P33
  33. P34